Skip to main content

Table 1 Economic model drug cost data and other economic model data

From: Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis

Drug cost, £+ ETN INF ADA GOL PSA Ref
First 3 months 2323.75 5043.21 2288.91 2288.91 Normal BSR guidelines [34] and MIMS [35]
Months 4-6 2323.75 2693.34 2288.91 2288.91
Subsequent 3 months 2323.75 2693.34 2288.91 2288.91   
Other data Mean SE PSA Ref
Change in cost for 1 U change in HAQ 106.5 69.3 Normal Kobelt 2002 [36]
Three-month cost for mild-to-moderate psoriasis if uncontrolled by biologics 205.2 9.3 Normal DoH 2007/2008 [37]
Three-month cost for psoriasis in remission 16.5 1 Normal Hartman 2003 [38]
Change in HAQ while on treatment per 3-month period 0 0.02 Normal Bojke 2011 [17] (expert elicitation)
Change in HAQ while not on treatment per 3-month period 0.018 0.007 Gamma Bojke 2011 [17] (NOAR estimate)
Log withdrawal rate from biologics per year -1.823 0.2044 Normal Bojke 2011 [17] (Registers)
Probability of PsARC response on placebo 0.249 0.0384 Beta Bojke 2011 [17] (Evidence synthesis)
Change in HAQ given a PsARC response on placebo -0.2436 0.04746 Normal Bojke 2011 [17] (Evidence synthesis)
Probability of PASI 75 response on placebo 0.044 0.009 Beta Bojke 2011 [17] (Evidence synthesis)
  1. +All costs inflated to 2010/11 values (£’s); ADA, Adalimumab 40 mg/2 weeks; BSR, British Society of Rheumatology; ETN, Etanercept 2×25 mg/week; INF, Infliximab 5 mg/kg/8 weeks; GOL, Golimumab 50 kg/4 weeks; HAQ, health assessment questionnaire; PsARC, Psoriatic Arthritis Response Criteria; PASI, Psoriasis Area and Severity Index; PSA, distribution used in probabilistic sensitivity analysis.
\